Monash IVF's Takeover Appeal Remains -- Market Talk

Dow Jones

Jan 14

2156 GMT - In vitro fertilization specialist Monash IVF may no longer be a bid target of a group including Washington H. Soul Pattinson, but Jefferies thinks its takeover appeal remains. Monash IVF last month said Soul Patts and Genesis Capital Investment Management had withdrawn their A$0.80/share offer. "We continue to believe that Monash IVF is a potentially attractive asset, and would not be surprised to see further potential corporate actions over time," analyst David Stanton says. Private equity has previously been interested in IVF specialists. Jefferies says that reflects the industry's high barriers to entry and supportive demographics. IVF is also a high cash flow business. Jefferies raises its price target on Monash IVF by 19% to A$0.95/share. Monash IVF ended Tuesday at A$0.745. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

January 13, 2026 16:56 ET (21:56 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603536996"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603536996\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603536996?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 05:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603536996","market":"hk","top_or_hot":-1,"title":"Monash IVF's Takeover Appeal Remains -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2156 GMT - In vitro fertilization specialist Monash IVF may no longer be a bid target of a group including <a href=\"https://laohu8.com/S/SOL.AU\">Washington H. Soul Pattinson</a>, but Jefferies thinks its takeover appeal remains. Monash IVF last month said Soul Patts and Genesis Capital Investment Management had withdrawn their A$0.80/share offer. \"We continue to believe that Monash IVF is a potentially attractive asset, and would not be surprised to see further potential corporate actions over time,\" analyst David Stanton says. Private equity has previously been interested in IVF specialists. Jefferies says that reflects the industry's high barriers to entry and supportive demographics. IVF is also a high cash flow business. Jefferies raises its price target on Monash IVF by 19% to A$0.95/share. Monash IVF ended Tuesday at A$0.745. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 16:56 ET (21:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monash IVF's Takeover Appeal Remains -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonash IVF's Takeover Appeal Remains -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-14 05:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2156 GMT - In vitro fertilization specialist Monash IVF may no longer be a bid target of a group including <a href=\"https://laohu8.com/S/SOL.AU\">Washington H. Soul Pattinson</a>, but Jefferies thinks its takeover appeal remains. Monash IVF last month said Soul Patts and Genesis Capital Investment Management had withdrawn their A$0.80/share offer. \"We continue to believe that Monash IVF is a potentially attractive asset, and would not be surprised to see further potential corporate actions over time,\" analyst David Stanton says. Private equity has previously been interested in IVF specialists. Jefferies says that reflects the industry's high barriers to entry and supportive demographics. IVF is also a high cash flow business. Jefferies raises its price target on Monash IVF by 19% to A$0.95/share. Monash IVF ended Tuesday at A$0.745. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 16:56 ET (21:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7113","symbol_name":"保健护理机构","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603536996","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603536996","pubTimestamp":1768341360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2156 GMT - In vitro fertilization specialist Monash IVF may no longer be a bid target of a group including Washington H. Soul Pattinson, but Jefferies thinks its takeover appeal remains. Monash IVF last month said Soul Patts and Genesis Capital Investment Management had withdrawn their A$0.80/share offer. \"We continue to believe that Monash IVF is a potentially attractive asset, and would not be surprised to see further potential corporate actions over time,\" analyst David Stanton says. Private equity has previously been interested in IVF specialists. Jefferies says that reflects the industry's high barriers to entry and supportive demographics. IVF is also a high cash flow business. Jefferies raises its price target on Monash IVF by 19% to A$0.95/share. Monash IVF ended Tuesday at A$0.745. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7113":"保健护理机构","MVF.AU":"MONASH IVF GROUP LTD","IVF":"INVO Fertility, Inc","BK4082":"医疗保健设备","BK7508":"医药生物股"},"translate_title":"莫纳什IVF的收购吸引力依然存在——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MVF.AU":0.9,"IVF":1.5},"content_text":"2156 GMT - In vitro fertilization specialist Monash IVF may no longer be a bid target of a group including Washington H. Soul Pattinson, but Jefferies thinks its takeover appeal remains. Monash IVF last month said Soul Patts and Genesis Capital Investment Management had withdrawn their A$0.80/share offer. \"We continue to believe that Monash IVF is a potentially attractive asset, and would not be surprised to see further potential corporate actions over time,\" analyst David Stanton says. Private equity has previously been interested in IVF specialists. Jefferies says that reflects the industry's high barriers to entry and supportive demographics. IVF is also a high cash flow business. Jefferies raises its price target on Monash IVF by 19% to A$0.95/share. Monash IVF ended Tuesday at A$0.745. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 16:56 ET (21:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}